Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Data Supports GlucoModicum's Needle-Free Glucose Monitor

Executive Summary

The Helsinki-based start-up has released data demonstrating the efficacy of its magnetohydrodynamic technology and how it could be used to measure blood glucose levels.

You may also be interested in...



JPM Day 1: Abbott Riding In Tandem With Libre 2 Plus & t:slim X2 News

The two diabetes players announced a new integration between their products.

Needles Are Out, Future Tech Is In, For Blood Glucose Measurement

Medtech Insight has spoken to several companies aiming to release devices that will replace current blood glucose monitors via disruptive, innovative technologies.

Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust

2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT146030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel